Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases... Show more
A.I.dvisor indicates that over the last year, PASG has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PASG jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To PASG | 1D Price Change % | ||
|---|---|---|---|---|
| PASG | 100% | +1.61% | ||
| AXON - PASG | 43% Loosely correlated | -0.21% | ||
| CYTK - PASG | 38% Loosely correlated | +1.89% | ||
| ARRY - PASG | 35% Loosely correlated | -8.86% | ||
| QTTB - PASG | 34% Loosely correlated | -0.11% | ||
| PRQR - PASG | 33% Poorly correlated | -5.07% | ||
More | ||||
a genetic medicines company, which focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options
Industry Biotechnology
On November 06, 2026, the Stochastic Oscillator for PASG moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In 62 of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PASG's RSI Indicator exited the oversold zone, 29 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PASG as a result. In 89 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for PASG just turned positive on October 29, 2026. Looking at past instances where PASG's MACD turned positive, the stock continued to rise in 44 of 49 cases over the following month. The odds of a continued upward trend are 90%.
Following a +4.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where PASG advanced for three days, in 172 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PASG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
PASG broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PASG entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PASG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.870) is normal, around the industry mean (3.498). P/E Ratio (-0.351) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PASG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.